Heartflow shares jumped 35.7% on Friday after the medical diagnostics company raised its 2026 full-year revenue guidance to $246 million–$250 million (40–42% growth), up from a prior forecast of 29–32%.
The company's AI platform turns heart images into 3D models to help doctors detect coronary artery disease non-invasively.
With Q2 revenue surging 48% year-over-year to $64.1 million and adjusted gross margin expanding to 83.3%, Heartflow is demonstrating both strong market demand and improving unit economics as it moves toward profitability.
What happened
Heartflow, a medical diagnostics company, raised its full-year 2026 revenue forecast to $246 million–$250 million (40–42% growth) from a prior forecast of 29–32% growth, and lifted its adjusted gross margin target to 82% from 81%.
Why it matters
The company's Heartflow One platform uses AI to create 3D heart models from coronary images, helping doctors detect artery disease non-invasively. With revenue up 48% year-over-year to $64.1 million in Q2 and adjusted gross margin climbing to 83.3% from 75.6%, the company is demonstrating both strong demand and improving profitability as it scales—signaling a path toward sustained profitable growth, according to CEO John Farquhar.
What to watch
Heartflow is not yet profitable overall, though its adjusted operating loss narrowed to $7.9 million from $11.5 million in the prior-year quarter. Investors should monitor whether the company reaches profitability as it executes on its 2026 guidance.
Heartflow, a medical diagnostics specialist, saw its stock surge 35.7% on Friday following the announcement of substantially raised full-year revenue guidance. The company now expects 2026 revenue of $246 million–$250 million, representing 40–42% growth, a significant upgrade from its prior forecast of 29–32% growth. The company also lifted its adjusted gross margin target to 82% from 81%.
The platform at the heart of Heartflow's business is Heartflow One, which uses cutting-edge artificial intelligence to transform coronary images into personalized 3D models of the heart. This technology provides doctors with a non-invasive way to locate arterial plaque and assess its impact on blood flow—a critical capability for managing coronary artery disease, which is the leading cause of death worldwide. The combination of accuracy, non-invasiveness, and clinical utility is driving strong adoption.
Heartflow's financial performance in the second quarter underscores this demand. Revenue surged 48% year-over-year to $64.1 million, while the company's adjusted gross margin expanded dramatically to 83.3% from 75.6% in the year-ago period. Although Heartflow is not yet profitable on a GAAP basis, its adjusted operating loss narrowed substantially to $7.9 million from $11.5 million in the prior-year quarter—a sign that the company is moving toward break-even. CEO John Farquhar said that "record gross margin and improving operating leverage demonstrate the increasing scalability of our model, giving us greater confidence in long-term, profitable growth." This statement encapsulates the investment thesis: a high-growth, high-margin business that is managing its costs effectively and on a clear trajectory to sustained profitability.
Heartflow's stock rally reflects investor confidence in both the company's near-term execution and its long-term trajectory. The 48% year-over-year revenue growth in Q2 to $64.1 million demonstrates strong market demand for its AI-powered coronary diagnostics platform, which addresses a significant medical need—coronary artery disease is the leading cause of death worldwide. What matters as much to investors is the company's path to profitability: adjusted gross margin expanded 7.7 percentage points year-over-year to 83.3%, while the adjusted operating loss contracted by nearly one-third, from $11.5 million to $7.9 million. This combination of revenue acceleration and improving unit economics suggests Heartflow's business model is scaling efficiently.
The company's decision to raise its full-year 2026 guidance—from 29–32% growth to 40–42%—signals that management sees durable demand and has confidence in its ability to convert that demand into revenue. Equally important, the lifted adjusted gross margin target to 82% reinforces management's expectation that the company will continue to improve profitability as it scales. CEO John Farquhar's statement about "record gross margin and improving operating leverage" reflects this view. For Heartflow to sustain this momentum, execution must match the raised guidance, and the company will need to demonstrate a credible path to full GAAP profitability—a milestone not yet reached but increasingly plausible given the current trend.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
Ask AI anything about this article. Q&As are published on this page for other readers too.
Meta's fair value estimate was trimmed from approximately US$828.80 to approximately US$754.10 in updated anal…
Nvidia has reduced its planned financial backstop for an OpenAI data center project in Ohio to less than $120…
Bank of America flagged that Broadcom's chip-financing vehicle could reach $370 billion of senior debt by mid-…
Broadcom's stock price dropped 6% amid concerns about $370 billion in AI-related debt and its impact on the co…
Polen Capital Management highlighted GE Vernova (NYSE:GEV) as a new position in its Q2 2026 investor letter, c…
BigBear.ai, an AI software provider to U.S
The AI news that matters, in one minute each morning.
Sign up free